Glenmark Pharmaceuticals (GLENMARK) Share Price Falls 2.38% as Stock Ends at Rs 2,383.80

Glenmark Pharmaceuticals Share Price fell to Rs 2,383.80 today, down 2.38% from the previous close, and the company’s market capitalisation stands at Rs 69,768.76 Cr. The move places Glenmark Pharmaceuticals in focus for Glenmark Pharmaceuticals Share Price Today searches, Glenmark Pharmaceuticals Stock News and Glenmark Pharmaceuticals Share Price Fall queries. The day’s data confirms the price event, but it does not establish a company-specific catalyst. In that setting, Univest is tracking the stock through a factual lens: what changed in the session, how the valuation compares with healthcare peers, and what the supplied fundamentals say about Glenmark Pharmaceuticals Share Price now.

Today’s decline also matters because the stock opened below the previous close and finished near the day’s lower end, while the company remains a Large Cap by the supplied market-cap category. Univest is using only the verified figures in this Glenmark Pharmaceuticals Share Price news update, without adding a reason that is not supported by the data.

Glenmark Pharmaceuticals (GLENMARK) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,383.8
Previous Close	Rs 2,442
Today's Move	-Rs 58.20 (-2.38%)
Open	Rs 2,422.7
High	Rs 2,433
Low	Rs 2,380.6
Turnover	Rs 5.08 crore
Market Capitalisation	Rs 69,768.76 crore
Market Cap Category	Large Cap

Glenmark Pharmaceuticals Share Price Today shows a clear down day in a session that began at Rs 2,422.70, compared with the previous close of Rs 2,442. The stock moved between a day high of Rs 2,433.00 and a day low of Rs 2,380.60 before ending at Rs 2,383.80. That leaves the day change at Rs -58.20, or -2.38%. In simple terms, Glenmark Pharmaceuticals Share Price moved lower from the opening print and settled close to the session low.

The turnover for the day is Rs 5.08 Cr. On the market-cap side, Glenmark Pharmaceuticals remains classified as a Large Cap, with market capitalisation of Rs 69,768.76 Cr. For readers following Glenmark Pharmaceuticals Share Price Live, the day’s numbers are important because they show a decline in the listed price without assigning a cause that the data does not verify. The session also keeps Glenmark Pharmaceuticals Stock News in focus for investors scanning same-day movers in the healthcare space. From here, the next useful step is to examine the company’s fundamentals, which help place the day’s share price fall in broader context.

Glenmark Pharmaceuticals (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 69,768.76 crore
P/E Ratio	38.33x
P/B Ratio	6.29x
ROE	14.1%
ROCE	20.35%
EPS	Rs 63.7
Book Value Per Share	Rs 388.43
Dividend Yield	0.1%

Glenmark Pharmaceuticals Share Price is trading against a valuation backdrop that includes a P/E ratio of 38.33 and a P/B ratio of 6.29. These numbers are above the same-industry medians of 32.73 for P/E and 2.95 for P/B, based on a 199-company benchmark set in Pharmaceuticals & Drugs. That comparison suggests the stock is priced richer than the industry median on both metrics, even before today’s decline is considered.

The company’s ROE stands at 14.10% and ROCE at 20.35%, both above the industry medians of 11.70% and 13.61% respectively. EPS is Rs 63.70, book value is Rs 388.43 and dividend yield is 0.10%. Those figures add useful depth to Glenmark Pharmaceuticals Fundamental Analysis because they show earnings per share, accounting net worth per share and the historical payout rate in one view. With Glenmark Pharmaceuticals Market Cap at Rs 69,768.76 Cr, Univest sees a profile that combines large-scale valuation, solid return ratios and a modest dividend yield. Glenmark Pharmaceuticals Financial Results and future disclosures will remain important for anyone tracking how the stock’s valuation compares with its own performance base, but the current article stays confined to the verified figures supplied here.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	38.33x
Benchmark Median P/E	32.73x
Benchmark Average P/E	49.58x
Benchmark P/E Range	3.48x to 757.76x
Company P/B Ratio	6.29x
Benchmark Median P/B	2.95x
Benchmark Average P/B	4.37x
Company ROE	14.1%
Benchmark Median ROE	11.7%
Benchmark Average ROE	10.7%
Company ROCE	20.35%
Benchmark Median ROCE	13.61%
Benchmark Average ROCE	13.4%
Company Market Capitalisation	Rs 69,768.76 crore
Benchmark Median Market Cap	Rs 804.62 crore
Benchmark Average Market Cap	Rs 14,476.05 crore

Glenmark Pharmaceuticals operates in Healthcare, within the Pharmaceuticals & Drugs industry, and the sector benchmark supplied here covers 199 companies in the same industry. In that benchmark, the company’s P/E of 38.33 sits above the median of 32.73 but below the average of 49.58. Its P/B of 6.29 is also above the industry median of 2.95 and below the average of 4.37? Actually, the supplied average is 4.37 and the company is above it, which keeps the stock on the richer side of the peer set on book-value terms.

On return ratios, Glenmark Pharmaceuticals’ ROE of 14.10% is above the industry median of 11.70% and the average of 10.70%. ROCE at 20.35% is also above the median of 13.61% and the average of 13.40%. The market-cap benchmark is broad: the same-industry median is Rs 804.62 Cr and the average is Rs 14,476.05 Cr, while the maximum reaches Rs 4,47,475.97 Cr. Against that field, Glenmark Pharmaceuticals Share Price reflects a company that is well above the typical industry size and sits in the Large Cap bracket. For Glenmark Pharmaceuticals Stock Analysis, the sector takeaway is straightforward: valuation is above the industry median, while return ratios also stand above the median and average. Univest notes that this combination can shape how investors read Glenmark Pharmaceuticals Share News, especially when a same-day decline appears against a higher-than-median valuation backdrop.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,47,475.97	36.76	5.14	14.85	19.11
Divi's Laboratories	DIVISLAB	2,54,763.56	87.25	14.45	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,423.19	86.07	20.91	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,16,658.07	26.08	4.37	19.69	21.39
Cipla	CIPLA	1,11,484.47	33.65	3.23	11.83	16

Glenmark Pharmaceuticals Share Price can also be read against the supplied peer set. The closest comparison points include Sun Pharmaceutical Industries at a P/E of 36.76 and market cap of Rs 4,47,475.97 Cr, Divi's Laboratories at a P/E of 87.25 and market cap of Rs 2,54,763.56 Cr, and Torrent Pharmaceuticals at a P/E of 86.07 and market cap of Rs 1,89,423.19 Cr. Zydus Lifesciences shows a P/E of 26.08 and market cap of Rs 1,16,658.07 Cr, while Cipla stands at a P/E of 33.65 and market cap of Rs 1,11,484.47 Cr.

On that set, Glenmark Pharmaceuticals’ P/E of 38.33 is higher than Sun Pharmaceutical and Cipla, but lower than Divi’s Laboratories and Torrent Pharmaceuticals. Its P/B of 6.29 is above Sun Pharmaceutical’s 5.14, Zydus Lifesciences’ 4.37 and Cipla’s 3.23, but below Divi’s Laboratories’ 14.45 and Torrent Pharmaceuticals’ 20.91. ROE at 14.10% sits below Zydus Lifesciences’ 19.69% and Torrent Pharmaceuticals’ 26.76%, while ROCE at 20.35% is above Sun Pharmaceutical’s 19.11% and Cipla’s 16.00%, but below Zydus Lifesciences’ 21.39% and Divi’s Laboratories’ 21.51%. For Glenmark Pharmaceuticals Share Price Today, the peer set shows a company that is neither the cheapest nor the most expensive in the basket, with return ratios that sit in the middle of the group.

Why Investors Are Watching Glenmark Pharmaceuticals

• Glenmark Pharmaceuticals Share Price fell 2.38% today to Rs 2,383.80 from the previous close of Rs 2,442.
• The day’s price range was Rs 2,380.60 to Rs 2,433.00, with opening price at Rs 2,422.70.
• Market capitalisation stands at Rs 69,768.76 Cr, and the company is classified as Large Cap.
• P/E of 38.33 and P/B of 6.29 place Glenmark Pharmaceuticals above the industry median on both valuation measures.
• ROE of 14.10%, ROCE of 20.35%, EPS of Rs 63.70 and book value of Rs 388.43 provide the main fundamental context.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals operates in Healthcare and is classified under the Pharmaceuticals & Drugs industry. The supplied data places it in the Large Cap category with a market capitalisation of Rs 69,768.76 Cr. For investors following Glenmark Pharmaceuticals Company News, the most relevant facts in this update are the sector classification, the valuation profile and the day’s share price movement. Glenmark Pharmaceuticals Share Price remains a stock-market event driven by verified session data and comparative financial metrics rather than by any unsupported narrative.

Track Glenmark Pharmaceuticals Share Price on Univest

Use Glenmark Pharmaceuticals (GLENMARK) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

Univest lets users track Glenmark Pharmaceuticals Share Price, Glenmark Pharmaceuticals Share Price Today, Glenmark Pharmaceuticals Stock News and Glenmark Pharmaceuticals Latest News in one place. Readers can also follow live price, financial ratios, shareholding pattern, 52-week levels and market insights on Univest for structured stock tracking.

Frequently Asked Questions

Why did Glenmark Pharmaceuticals Share Price fall today?

Ans.  The supplied data shows Glenmark Pharmaceuticals Share Price fell 2.38% to Rs 2,383.80, but it does not establish a company-specific catalyst. The article therefore treats this as a verified price event only.

What is Glenmark Pharmaceuticals Share Price Today?

Ans.  Glenmark Pharmaceuticals Share Price Today is Rs 2,383.80, compared with the previous close of Rs 2,442. The stock declined Rs 58.20 during the session and finished near the day’s low.

What is Glenmark Pharmaceuticals market capitalisation?

Ans.  Glenmark Pharmaceuticals has a market capitalisation of Rs 69,768.76 Cr. The supplied market-cap category is Large Cap, which provides company-size context alongside the day’s share price fall and valuation data.

How does Glenmark Pharmaceuticals compare on valuation?

Ans.  Glenmark Pharmaceuticals has a P/E of 38.33 and P/B of 6.29. Both are above the industry medians of 32.73 and 2.95 in the same Pharmaceuticals & Drugs benchmark. The company trades at a P/E ratio of 38.33x.

What do ROE and ROCE show for Glenmark Pharmaceuticals?

Ans.  Glenmark Pharmaceuticals reports ROE of 14.10% and ROCE of 20.35%. Both are above the same-industry medians, which gives useful context for Glenmark Pharmaceuticals Share Price and its valuation profile. ROE stands at 14.1%.

How does Glenmark Pharmaceuticals compare with healthcare peers?

Ans.  Glenmark Pharmaceuticals sits between peers on key metrics. Its P/E of 38.33 is above Cipla and Sun Pharmaceutical, but below Divi’s Laboratories and Torrent Pharmaceuticals, while ROCE is above Sun Pharmaceutical and Cipla.